MEK 162

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, University Health Network, Toronto

Conditions

Biliary Tract CarcinomaGallbladder CarcinomaLeukemia

Phase 1

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

TerminatedNCT02089230

M.D. Anderson Cancer CenterLeukemia

Start: 2014-08-27End: 2019-06-05Updated: 2021-04-20

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

WithdrawnNCT02105350

University Health Network, TorontoBiliary Tract Carcinoma, Gallbladder Carcinoma

Start: 2015-06-30End: 2015-06-30Updated: 2018-02-19